arrow
C

Chiara Costanza Volpi

fondazione irccs istituto tumori milano
H指数:24
被引数:2,202

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature

ICIs在TNBC中的超长应答:解决最佳ICI治疗持续时间的问题。两例病例及文献综述

2025-11-070
OAAI
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei

腹膜假性粘液瘤中A2AR的表达和免疫抑制环境与KRAS和GNAS突变无关

2023-07-204
OAAI
Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world

将HER2-low乳腺癌预测和预后数据从临床试验转移到现实世界

2022-09-2619
OAAI
The landscape of d16HER2 splice variant expression across HER2-positive cancers (vol 9, 3545, 2019)

HER2-positive癌症中d16HER2剪接变体表达的景观 (第9卷,3545卷,2019)

2020-04-240
OAAI
The landscape of d16HER2 splice variant expression across HER2-positive cancers

HER2-positive癌症中d16HER2剪接变体表达的前景

2019-03-0526
OAAI
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

HER2-Positive转移性胃癌患者曲妥珠单抗原发性耐药的生物标志物: 健忘症病例对照研究

2018-02-2877
OAAI
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

转移性结直肠癌患者抗EGFR单克隆抗体的阴性超选择: 紧迫的病例对照研究

2017-12-0183
OAAI
Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
2017-07-010
PRE
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

结直肠癌中MET和BRAF抑制进展中MET超扩增的出现

2017-06-2731
OAAI
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性

2017-05-14141
OAAI
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

曲妥珠单抗治疗后HER2-positive胃癌或胃食管癌的HER2丢失: 对进一步临床研究的意义

2016-09-16106
OAAI